A new urea-activated nanocarrier concept is targeting sodium-glucose cotransporter 2 (SGLT2) inhibition with a site-specific approach designed for metabolic and kidney health. The study describes a urea-triggered delivery mechanism developed by Ren, Gao, Yun, and colleagues to concentrate activity where it is intended. The positioning matters because SGLT2 therapies are central to type 2 diabetes and cardiorenal risk management, and delivery technologies are increasingly used to improve localization and reduce off-target exposure. The report expands the innovation pipeline for SGLT2-adjacent strategies, combining known pharmacology with a new activation/depot mechanism.